Revolution Medicines, Inc.RVMD
Market cap
$14.7B
P/E ratio
| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Collaboration Revenue | - | 29 | 35 | - | - |
| Total revenue | 43 | 29 | 35 | 12 | - |
| Research and development | 132 | 187 | 253 | 423 | 592 |
| General and administrative | 21 | 30 | 41 | 76 | 97 |
| Total operating expenses | 154 | 217 | 294 | 499 | 690 |
| Loss from operations | -111 | -188 | -258 | -487 | -690 |
| Interest income | 2 | 1 | 9 | 47 | 87 |
| Other expense | - | - | - | 0 | 3 |
| Change in fair value of warrant liability and contingent earn-out shares | - | - | - | 0 | 4 |
| Total other income, net | 2 | 1 | 9 | 47 | 89 |
| Loss before income taxes | -109 | -187 | -249 | -440 | -601 |
| Benefit from income taxes | -0 | - | -0 | -3 | -1 |
| Net loss | -108 | -187 | -249 | -436 | -600 |
| Earnings Per Share, Basic | - | - | -3.08 | -3.86 | -3.58 |
| Earnings Per Share, Diluted | - | - | -3.08 | -3.86 | -3.58 |
| Net loss | -108 | -187 | -249 | -436 | -600 |
| Unrealized gain (loss) on investments, net | - | - | - | 2 | 1 |
| Comprehensive loss | - | - | - | -434 | -599 |